Vaccinations in patients with immune-mediated inflammatory diseases

Rheumatology

Volumn 49, Issue 10, 2010, Pages 1815-1827

  Rahier, Jean François ^a   Moutschen, Michel ^b   van Gompel, Alfons ^c   van Ranst, Marc ^d   Louis, Edouard ^e   Segaert, Siegfried ^d   Masson, Pierre ^f   de Keyser, Filip ^g  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f DE DUVE INSTITUTE   (Belgium)

^g GHENT UNIVERSITY   (Belgium)

Author keywords

Immune mediated inflammatory disease; Infection; Inflammatory bowel disease; Psoriasis; Review; Rheumatoid arthritis; Vaccination; Vaccine preventable disease

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID; GOLD SALT; GOLIMUMAB; HEPATITIS VACCINE; IMMUNOMODULATING AGENT; INACTIVATED VACCINE; INFLIXIMAB; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; METHOTREXATE; PNEUMOCOCCUS VACCINE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; UNINDEXED DRUG; USTEKINUMAB; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

AUTOIMMUNITY; BIOLOGICAL THERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE MEDIATED INFLAMMATORY DISEASE; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOTHERAPY; INCIDENCE; INFECTION RISK; INFLUENZA; INFORMATION RETRIEVAL; MORBIDITY; MORTALITY; PNEUMOCOCCAL INFECTION; POPULATION RESEARCH; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT CONTRAINDICATION; VACCINATION;

HUMANS; IMMUNIZATION SCHEDULE; IMMUNOCOMPROMISED HOST; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PSORIASIS; RISK FACTORS; VACCINATION; VACCINES;

EID: 77956860976     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq183     Document Type: Review

References (107)

1. Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007;83:251-60.
2. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. Br Med J 1999;318: 593-6.
3. Doria A, Zampieri S, Sarzi-Puttini P. Exploring the complex relationships between infections and autoimmunity. Autoimmun Rev 2008;8:89-91.
4. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46: 2287-93.
5. Mikuls TR. Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:729-52.
6. Baum J. Infection in rheumatoid arthritis. Arthritis Rheum 1971;14:135-7.
7. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
8. Naz SM, Symmons DP. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21:871-83.
9. Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity 2005;38:473-85.
10. Iliopoulos AG, Tsokos GC. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 1996;25:318-36.
11. Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology 2002;122:1808-14.
12. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003;125:1576-82.
13. Irving PM, Gibson PR. Infections and IBD. Nat Clin Pract Gastroenterol Hepatol 2008;5:18-27.
14. Casanova JL, Abel L. Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J Exp Med 2009;206:1839-43.
15. Chandra RK. Nutrition, immunity and infection: from basic knowledge of dietary manipulation of immune responses to practical application of ameliorating suffering and improving survival. Proc Natl Acad Sci USA 1996;93:14304-7.
16. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986;172:298-304.
17. Kimball AB, Gladman D, Gelfand JM et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58:1031-42.
18. Chiu LM, Domagala BM, Park JM. Management of opportunistic infections in solid-organ transplantation. Prog Transplant 2004;14:114-29.
19. Liu Z, Yuan X, Luo Y et al. Evaluating the effects of immunosuppressants on human immunity using cytokine profiles of whole blood. Cytokine 2009;45:141-7.
20. Jong EC, Freedman DO. The immunocompromised traveler. CDC Travelers' Health Yellow Book. Atlanta, GA, USA: Centers for Disease Control and Prevention. http://wwwn.cdc.gov/travel/yellowbook/2010/chapter-8/immu-nocompromised-traveler.aspx. (10 September 2009, date last accessed).
21. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11:954-63.
22. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1074-81.
23. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology 2007;46:1157-60.
24. Martin-Mola E, Balsa A. Infectious complications of biologic agents. Rheum Dis Clin North Am 2009;35:183-99.
25. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010;39:327-46.
26. Salliot C, Gossec L, Ruyssen-Witrand A et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology 2007; 46:327-34.
27. Schiff M, Keiserman M, Codding C et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
28. Colombel JF, Loftus EV Jr, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
29. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30.
30. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009;30:253-64.
31. Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134: 929-36.
32. Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58: 501-8.
33. Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med 2009;360:1981-8.
34. Gluck T, Muller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis 2008;46:1459-65.
35. Melmed GY, Ippoliti AF, Papadakis KA et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006; 101:1834-40.
36. Conti F, Rezai S, Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev 2008;8:124-8.
37. Gross K, Combe C, Kruger K, Schattenkirchner M. Arthritis after hepatitis B vaccination Report of three cases. Scand J Rheumatol 1995;24:50-2.
38. Ascherio A, Zhang SM, Hernan MA et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001;344:327-32.
39. Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis 2007;66: 1384-7.
40. Borte S, Liebert UG, Borte M, Sack U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology 2009;48:144-8.
41. Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet 2003;362:1659-66.
42. Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005;38:235-45.
43. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979;110:105-23.
44. Lasky T, Terracciano GJ, Magder L et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-802.
45. Evans D, Cauchemez S, Hayden FG. "Prepandemic" immunization for novel influenza viruses, "swine flu" vaccine, Guillain-Barre syndrome, and the detection of rare severe adverse events. J Infect Dis 2009;200:321-8.
46. Duclos P. Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin Drug Saf 2003;2:225-31.
47. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001;344:319-26.
48. Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun 2001;16:309-18.
49. Benjamin CM, Chew GC, Silman AJ. Joint and limb symptoms in children after immunisation with measles, mumps and rubella vaccine. Br Med J 1992;304:1075-8.
50. Aho K, Konttinen A, Rajasalmi M, Wager O. Transient appearance of the rheumatoid factor in connection with prophylactic vaccinations. Acta Pathol Microbiol Scand 1962;56:478-9.
51. AFSSAPS (Agence Française de Sécurité Sanitaire des Produits de Santé). Vaccination anti hépatite B - Saint-Denis Cedex, France: Mise à jour des données et des études de pharamcovigilance, 2000.
52. Lee K, Hall AJ. Hepatitis B vaccination and putative associations with (a) arthritis (b) chronic fatigue syndrome London School of Hygiene and Tropical Medicine: WHO - GACVS (Global Advisory Committee on Vaccine Safety), 2005.
53. Geier DA, Geier MR. A one year followup of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Clin Exp Rheumatol 2002;20:767-71.
54. Geier MR, Geier DA. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review. Clin Exp Rheumatol 2004;22:749-55.
55. Pope JE, Stevens A, Howson W, Bell DA. The development of rheumatoid arthritis after recombinant hepatitis B vaccination. J Rheumatol 1998;25:1687-93.
56. Lewin J, Dhillon AP, Sim R, Mazure G, Pounder RE, Wakefield AJ. Persistent measles virus infection of the intestine: confirmation by immunogold electron microscopy. Gut 1995;36:564-9.
57. Ekbom A, Daszak P, Kraaz W, Wakefield AJ. Crohn's disease after in-utero measles virus exposure. Lancet 1996;348:515-7.
58. Ekbom A, Wakefield AJ, Zack M, Adami HO. Perinatal measles infection and subsequent Crohn's disease. Lancet 1994;344:508-10.
59. Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ. Is measles vaccination a risk factor for inflammatory bowel disease? Lancet 1995;345:1071-4.
60. Feeney M, Ciegg A, Winwood P, Snook J. A case-control study of measles vaccination and inflammatory bowel disease. The East Dorset Gastroenterology Group. Lancet 1997;350:764-6.
61. Davis RL, Kramarz P, Bohlke K et al. Measles-mumpsrubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Arch Pediatr Adolesc Med 2001;155:354-9.
62. Bernstein CN, Rawsthorne P, Blanchard JF. Population-based case-control study of measles, mumps and rubella and inflammatory bowel disease. Inflamm Bowel Dis 2007;13:759-62.
63. Davis RL, Bohlke K. Measles vaccination and inflammatory bowel disease: controversy laid to rest? Drug Saf 2001;24:939-46.
64. Baron S, Turck D, Leplat C et al. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut 2005;54:357-63.
65. Rousseau MC, Parent ME, St-Pierre Y. Potential health effects from non-specific stimulation of the immune function in early age: the example of BCG vaccination. Pediatr Allergy Immunol 2008;19:438-48.
66. Takayama K, Satoh T, Hayashi M, Yokozeki H. Psoriatic skin lesions induced by BCG vaccination. Acta Derm Venereol 2008;88:621-2.
67. Pattison E, Harrison BJ, Griffiths CE, Silman AJ, Bruce IN. Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis 2008;67:672-6.
68. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:1-48.
69. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003;81:61-70.
70. Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis 2008;8:642-9.
71. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007;196:1304-12.
72. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008;47:401-9.
73. Mast EE, Weinbaum CM, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55:1-33.
74. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002;61:623-5.
75. Kuruma KA, Borba EF, Lopes MH, de Carvalho JF, Bonfa E. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 2007;16:350-4.
76. Kapetanovic MC, Saxne T, Sjoholm A, Truedsson L, Jonsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology 2006; 45:106-11.
77. Elkayam O, Paran D, Caspi D et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002;34:147-53.
78. Elkayam O, Ablin J, Caspi D. Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Autoimmun Rev 2007;6:312-4.
79. Mease PJ, Ritchlin CT, Martin RW et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004;31:1356-61.
80. Melmed GY, Agarwal N, Frenck RW et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:148-54.
81. Bingham CO III, Looney RJ, Deodhar A et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010;62:64-74.
82. Krueger JG, Ochs HD, Patel P, Gilkerson E, Guttman-Yassky E, Dummer W. Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. J Invest Dermatol 2008; 128:2615-24.
83. Tay L, Leon F, Vratsanos G, Raymond R, Corbo M. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther 2007;9:R38.
84. Fomin I, Caspi D, Levy V et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006;65:191-4.
85. Gelinck LB, van der Bijl AE, Beyer WE et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008;67:713-6.
86. Del Porto F, Lagana B, Biselli R et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 2006;24:3217-23.
87. Holvast A, Huckriede A, Wilschut J et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006;65:913-8.
88. Salemi S, Picchianti-Diamanti A, Germano V et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin Immunol 2010; 134:113-20.
89. Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:851-6.
90. Lu Y, Jacobson DL, Ashworth LA et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009; 104:444-53.
91. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology 2007;46:608-11.
92. Oren S, Mandelboim M, Braun-Moscovici Y et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008;67:937-41.
93. Van Assen S, Holvast A, Benne CA et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010;62: 75-81.
94. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57:1-30.
95. Rahier JF, Ben-Horin S, Chowers Y et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2009;3:47-91.
96. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:1-13.
97. The Immunocompromised Traveller. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2007;33:1-24.
98. Nieminen R, Vuolteenaho K, Riutta A et al. Aurothiomalate inhibits COX-2 expression in Vaccination and IMID chondrocytes and in human cartilage possibly through its effects on COX-2 mRNA stability. Eur J Pharmacol 2008;587:309-16.
99. Vaccinations in the immunocompromised person. Guidelines for the patient taking immunosuppressantzs, steroids and the new biologic therapies. London: British Society for Rheumatology. 2002.
100. Lebwohl M, Bagel J, Gelfand JM et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008;58:94-105.
101. Kasapcopur O, Cullu F, Kamburoglu-Goksel A et al. Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1128-30.
102. Battafarano DF, Battafarano NJ, Larsen L et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998;41: 1828-34.
103. Chalmers A, Scheifele D, Patterson C et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 1994;21:1203-6.
104. Ravikumar R, Owen T, Barnard J. Anti-TNF therapy in RA patients alters hepatitis B vaccine responses. Arthritis Rheum 2006;56(Suppl 9):S36.
105. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007;34:272-9.
106. Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007;34:952-7.
107. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004;33:283-8.